We looked at the domains of technical merit, scientific merit and the supply chain.
In terms of scientific merit, there were subclassifications. We kind of had a rubric with all of those three domains. Some of the vaccine platforms that arose during the COVID pandemic were very novel. We wanted to know all of the background evidence that would support platforms like them. We looked at the ones that used platforms we were aware of and the safety and efficacy with similar platforms for other vaccines.
In terms of technical merit, we looked at the companies' proposals for clinical development and for good manufacturing practice in the whole process before you can first inject an investigational product into a human.
Then lastly, there's the whole process for scale-up and delivery. For that, I would turn to my colleague Mark Lievonen to describe our rubric.